{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"A DLT was any of the adverse events that starts on or after the first administration of study drug listed below, as defined by the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0.\n\n* Any Grade(G) ≥3 nonhematologic toxicity except G3 fatigue, nausea, tendon reflex decrease, weight gain attributable to normal growth and development.\n* G3 vomiting/diarrhea was DLT only if it persists \\>48 h despite standard of care treatment.\n* G4 vomiting/diarrhea was DLT regardless of duration.\n* Any toxicity, regardless of the NCI CTCAE v5.0 grade, resulting in discontinuation or dose reduction of treatment (except symptoms related to progressive disease (PD)).\n* G4/G3 thrombocytopenia with G1 or higher bleeding.\n* G4 anemia lasting \\>8 days, despite supportive therapy.\n* G4 neutropenia, lasting \\>8 days, despite supportive therapy","groups":[{"description":"Participants received selpercatinib given orally BID, with the dose based on body surface area in a 28-day cycle. The starting dose level of 92mg/m\\^2 (maximum160 mg BID) was intended to deliver equivalent exposure to the RP2D in adults.","id":"OG000","title":"Dose Escalation Cohort (Phase 1)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants in Phase 1 of the study who received at least one dose of the study drug.","reportingStatus":"POSTED","timeFrame":"Cycle 1 (28 Day Cycle)","title":"Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs)","type":"PRIMARY","unitOfMeasure":"Participants"}